Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N3.H2O4S |
Molecular Weight | 363.431 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.C(N(CC1=CC=CC=C1)C2=CC=CC=C2)C3=NCCN3
InChI
InChIKey=UWOSJBSLQYMGDL-UHFFFAOYSA-N
InChI=1S/C17H19N3.H2O4S/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;1-5(2,3)4/h1-10H,11-14H2,(H,18,19);(H2,1,2,3,4)
DescriptionSources: https://www.drugbank.ca/drugs/DB08799Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68000865
Sources: https://www.drugbank.ca/drugs/DB08799
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68000865
Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3943 Sources: https://www.drugbank.ca/drugs/DB08799 |
38.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | VASOCON-A Approved UseTemporary relief of ocular redness and itching. Launch Date1990 |
PubMed
Title | Date | PubMed |
---|---|---|
Neuroprotective activity of antazoline against neuronal damage induced by limbic status epilepticus. | 2003 |
|
Conjunctival allergen challenge: models in the investigation of ocular allergy. | 2003 Jul |
|
Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats. | 2003 Nov |
|
Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. | 2005 Jul-Aug |
|
Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. | 2007 Jun 22 |
|
[Histamine and the convulsive threshold or effectiveness of antiepileptic drugs]. | 2008 |
|
Demand for food and cocaine in Fischer and Lewis rats. | 2009 Feb |
|
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. | 2009 Oct 23 |
|
Evidence for the involvement of the noradrenergic system, dopaminergic and imidazoline receptors in the antidepressant-like effect of tramadol in mice. | 2010 May |
|
Simultaneous determination of antazoline and naphazoline by the net analyte signal standard addition method and spectrophotometric technique. | 2010 Nov-Dec |
|
Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. | 2010 Sep-Oct |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.empr.com/vasocon-a/drug/1227/
1-2 drops up to 4 times daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7714409
The antihistaminic agent, antazoline, was tested for its ability to compete for [3H]pyrilamine, [3H]tiotidine and [3H]N-methyl histamine binding to rodent brain H1, H2 and H3 histamine receptors, respectively. Antazoline exhibited the highest affinity for H1-receptors (dissociation constant, Ki = 38.4 +/- 4.4 nM), and was considerably weaker at H2- (K1 = 44,433 +/- 1,763 nM) and H3-receptors (Ki = 42,400 +/- 7,527 nM).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092149
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
DBSALT000910
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
24359-81-7
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
SUB00542MIG
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
DTXSID30179096
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
6T74I07212
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
3084423
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY | |||
|
C95310
Created by
admin on Fri Dec 15 17:15:01 GMT 2023 , Edited by admin on Fri Dec 15 17:15:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD